Personalising acute myologic leukaemia treatment using a new algorithm and integrating patient preferences in personal medicine.

  • Period: 2020-01-01 – 2022-12-31
  • Budget: 4,340,000 SEK
  • Funder: Swedish Research Council
  • Type of funding: Projektbidrag

Personalised cancer treatment & patient preferences

Patients suffering from acute myologic leukaemia (AML) respond very differently to available treatments. Now, researchers in the multidisciplinary project MEET-AML (funded by the Swedish Research Council) hope to be able to tailor treatment for individual patients with the aid of a new algorithm targeting vulnerabilities in cancerous cells using -omics-data.

Using a new algorithm and integrating patient preferences, researchers in Italy, Spain, France, Germany, Finland, and Sweden will spend 3 years developing new treatments for acute myologic leukaemia, a cancer type of cancer where personalised treatment has not previously been available.

But it’s not just the vulnerabilities in the leukaemia cells the researchers are interested in. MEET-AML will also develop ways of integrating patient preferences, what they want and how they make benefit-risk trade-offs, into the personalised treatment. Raising important questions of when and how to integrate patient preferences in medical decision-making.

Researchers from Uppsala University’s Centre for Research Ethics & Bioethics will perform quantitative and qualitative studies about AML-patients’ preferences in Finland, Germany and Italy.

  • Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) srl, IRCCS, Italy
  • Charité University Medicine Berlin, Germany
  • University of Helsinki, Finland
  • Inserm Délégation Régionale Nord Ouest, France
  • University of Navarra, Spain
  • Uppsala University's Centre for Research Ethics & Bioethics, Sweden

People in the project